Established organ damage reduces belimumab efficacy in systemic lupus erythematosus

Ann Rheum Dis. 2019 Jul;78(7):1006-1007. doi: 10.1136/annrheumdis-2018-214880. Epub 2019 Jan 4.

Authors

Ioannis Parodis^{1

2}, Alvaro Gomez^{3

2}, Sharzad Emamikia^{3

2}, Katerina Chatzidionysiou^{3

2}

Affiliations

¹ Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden ioannis.parodis@ki.se.
² Rheumatology, Karolinska University Hospital, Stockholm, Sweden.
³ Division of Rheumatology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.

PMID: 30610063
DOI: 10.1136/annrheumdis-2018-214880

No abstract available

Keywords: belimumab; biologics; organ damage; systemic lupus erythematosus; treatment.

Publication types

Evaluation Study
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antibodies, Monoclonal, Humanized / therapeutic use*
Female
Humans
Immunosuppressive Agents / therapeutic use*
Logistic Models
Lupus Erythematosus, Systemic / drug therapy*
Lupus Erythematosus, Systemic / pathology*
Male
Middle Aged
Randomized Controlled Trials as Topic
Severity of Illness Index*
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Immunosuppressive Agents
belimumab